Phibro Animal Health Corporation $PAHC Shares Acquired by Voya Investment Management LLC

Voya Investment Management LLC lifted its position in shares of Phibro Animal Health Corporation (NASDAQ:PAHC) by 44.3% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,894 shares of the company’s stock after purchasing an additional 9,796 shares during the period. Voya Investment Management LLC owned about 0.08% of Phibro Animal Health worth $681,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its position in shares of Phibro Animal Health by 0.4% during the first quarter. Vanguard Group Inc. now owns 1,521,520 shares of the company’s stock worth $32,500,000 after purchasing an additional 6,784 shares in the last quarter. Acadian Asset Management LLC lifted its position in shares of Phibro Animal Health by 0.5% during the first quarter. Acadian Asset Management LLC now owns 782,939 shares of the company’s stock worth $16,713,000 after purchasing an additional 4,144 shares in the last quarter. Nuveen LLC acquired a new position in shares of Phibro Animal Health during the first quarter worth $10,312,000. Invesco Ltd. lifted its position in shares of Phibro Animal Health by 92.3% during the first quarter. Invesco Ltd. now owns 387,739 shares of the company’s stock worth $8,282,000 after purchasing an additional 186,087 shares in the last quarter. Finally, Millennium Management LLC raised its holdings in Phibro Animal Health by 74.3% in the first quarter. Millennium Management LLC now owns 362,030 shares of the company’s stock valued at $7,733,000 after acquiring an additional 154,281 shares in the last quarter. 99.34% of the stock is owned by institutional investors and hedge funds.

Phibro Animal Health Stock Down 0.5%

Shares of NASDAQ:PAHC opened at $38.04 on Friday. The stock has a market capitalization of $1.54 billion, a price-to-earnings ratio of 32.24, a price-to-earnings-growth ratio of 1.14 and a beta of 0.89. Phibro Animal Health Corporation has a 1-year low of $16.16 and a 1-year high of $41.57. The company’s fifty day moving average is $33.48 and its two-hundred day moving average is $26.48. The company has a debt-to-equity ratio of 2.46, a quick ratio of 1.25 and a current ratio of 2.76.

Phibro Animal Health (NASDAQ:PAHC) last issued its earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.52 by $0.05. The company had revenue of $378.70 million for the quarter, compared to analysts’ expectations of $362.24 million. Phibro Animal Health had a net margin of 3.73% and a return on equity of 32.14%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS. Equities analysts anticipate that Phibro Animal Health Corporation will post 1.95 EPS for the current year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 24th. Investors of record on Wednesday, September 3rd were issued a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend was Wednesday, September 3rd. Phibro Animal Health’s dividend payout ratio (DPR) is 40.68%.

Insider Buying and Selling at Phibro Animal Health

In related news, CEO Jack Bendheim sold 7,022 shares of the stock in a transaction dated Thursday, September 18th. The shares were sold at an average price of $40.26, for a total value of $282,705.72. Following the sale, the chief executive officer owned 31,338 shares of the company’s stock, valued at $1,261,667.88. This trade represents a 18.31% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last 90 days, insiders have sold 24,622 shares of company stock valued at $995,893. 50.07% of the stock is owned by company insiders.

Analyst Ratings Changes

Several brokerages have weighed in on PAHC. JPMorgan Chase & Co. raised shares of Phibro Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $25.00 to $35.00 in a report on Monday, July 7th. BNP Paribas raised shares of Phibro Animal Health to a “hold” rating in a research report on Monday, June 16th. Zacks Research downgraded shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 28th. Morgan Stanley set a $34.00 target price on shares of Phibro Animal Health in a research report on Thursday, August 28th. Finally, BNP Paribas Exane raised shares of Phibro Animal Health from an “underperform” rating to a “neutral” rating and set a $24.00 target price for the company in a research report on Monday, June 16th. One equities research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Reduce” and an average target price of $28.40.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.